DELLAVEDOVA, GIULIA
 Distribuzione geografica
Continente #
EU - Europa 65
AS - Asia 41
NA - Nord America 32
AF - Africa 2
OC - Oceania 1
Totale 141
Nazione #
US - Stati Uniti d'America 32
IT - Italia 23
CN - Cina 12
IE - Irlanda 12
RU - Federazione Russa 12
HK - Hong Kong 11
SG - Singapore 9
FI - Finlandia 6
KR - Corea 5
GB - Regno Unito 4
IN - India 3
NL - Olanda 3
EG - Egitto 2
FR - Francia 2
AU - Australia 1
CH - Svizzera 1
DE - Germania 1
DK - Danimarca 1
JP - Giappone 1
Totale 141
Città #
Dublin 11
Hong Kong 11
Milan 10
Singapore 8
Helsinki 4
Shanghai 4
Santa Clara 3
Turin 3
Bergamo 2
Boston 2
Cairo 2
Chengdu 2
Lappeenranta 2
Los Angeles 2
Manchester 2
Moscow 2
New York 2
Orléans 2
Perugia 2
Rotterdam 2
San Francisco 2
Santa Cruz 2
Seoul 2
Yeonsu-gu 2
Ashburn 1
Bari 1
Bethesda 1
Chongqing 1
Dallas 1
Delhi 1
Desio 1
Dietikon 1
Dongguan 1
Frankfurt am Main 1
Frederiksberg 1
Mediglia 1
Melzo 1
Peterborough 1
Potomac 1
Romola 1
San Marcos 1
Tokyo 1
Totale 104
Nome #
STRATEGIES TO OVERCOME OLAPARIB DRAWBACKS: FROM PATIENT SELECTION TO NOVEL THERAPIES 79
The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases 30
The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin 28
The next generation PARP inhibitor AZD5305 is active in a broad range of pre-clinical models of ovarian cancer 18
Totale 155
Categoria #
all - tutte 1.046
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.046


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024103 0 0 0 15 5 6 7 36 4 15 7 8
2024/202552 9 13 5 7 14 4 0 0 0 0 0 0
Totale 155